Jodi Biller
Family · Scott Depot, WVNPI 1457798266
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $21,330 of the $28,589 with a category attached, or 74.6%. 22 manufacturers reported payments, led by AstraZeneca at 48.2% of the total. Reporting peaked in 2021 at $16,517 and has fallen 95.0% since, to $823 in 2025. Among family clinicians in WV with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 313 payments — averaging $91.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$14K
- GSK$10K
- Boehringer Ingelheim$3K
- Pulmonx Corporation$1K
- Regeneron Healthcare Solutions, Inc.$530
- Sanofi$256
- plus $642 from 16 others
What the payments were for
- Consulting fees$6252%
- Speaking & faculty fees$21,33075%
- Travel & lodging$1,2724%
- Food & beverage$5,33419%
- Education$270%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 70 | $13,784 |
| GSK | 109 | $9,504 |
| Boehringer Ingelheim | 23 | $2,551 |
| Pulmonx Corporation | 25 | $1,322 |
| Regeneron Healthcare Solutions, Inc. | 35 | $530 |
| Sanofi | 13 | $256 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $85 |
| Verona Pharma, Inc. | 5 | $82 |
| Philips North America LLC | 4 | $81 |
| Exact Sciences | 3 | $59 |
| AbbVie | 3 | $54 |
| Advanced Respiratory, Inc | 3 | $49 |
| Insmed, Inc. | 2 | $43 |
| Novartis | 2 | $34 |
| Genentech USA, Inc. | 3 | $33 |
| Grifols USA, LLC | 1 | $25 |
| Apria Healthcare LLC | 1 | $21 |
| Baxter Healthcare | 1 | $17 |
| Novo Nordisk | 1 | $15 |
| Teva Pharmaceuticals USA, Inc. | 1 | $15 |
| Inogen, Inc. | 1 | $15 |
| Axsome Therapeutics, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FASENRA$11,733
- NUCALA$8,400
- BREZTRI$1,001
- CHARTIS CATHETER$886
- ZEPHYR ENDOBRONCHIAL VALVE$886
- ZEPHYR DELIVERY CATHETER$886
- PULMONX CHARTIS TABLET CONSOLE$886
- TEZSPIRE$376
- FARXIGA$169
How this compares
$28,589 in reported general payments places this provider in the 95th percentile of 1,507 family providers in West Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 207 | $311,490 |
| OfevNintedanib Esylate | 15 | $182,763 |
| Dupixent PenDupilumab | 27 | $96,997 |
| NucalaMepolizumab | 25 | $90,496 |
| TezspireTezepelumab-Ekko | 17 | $72,366 |
| EliquisApixaban | 44 | $64,425 |
| Breo ElliptaFluticasone/Vilanterol | 56 | $47,431 |
| Spiriva RespimatTiotropium Bromide | 32 | $42,767 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 40 | $39,032 |
| Advair HfaFluticasone Propion/Salmeterol | 53 | $33,581 |
| SymbicortBudesonide/Formoterol Fumarate | 60 | $32,590 |
| Incruse ElliptaUmeclidinium Bromide | 35 | $22,599 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 15 | $17,265 |
| OzempicSemaglutide | 15 | $16,396 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 227 | $13,723 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Nucala, Breo Ellipta, Incruse Ellipta, Anoro Ellipta | $9,504 | $489,281338 claims |
| Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat, Combivent Respimat | $2,551 | $271,687102 claims |
| AstraZenecaTezspire, Symbicort | $13,784 | $104,95677 claims |
| Novo NordiskOzempic | $15 | $16,39615 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,507 family providers in West Virginia.
Other family in Scott Depot
- Gina LatheyScott Depot$31K
- Jennifer ShortScott Depot$10K
- Ashley ComerCharleston$213K
- Dana CruseParkersburg$109K
- Sarah KnightCharleston$99K
- Star RoeBarboursville$55K
- Angela SettleCharleston$51K
- Amber DuncanCross Lanes$44K
- Jennifer FieldsHuntington$32K
- Misty BareboHuntington$25K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.